Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

OBJECTIVES:

I. Determine the response rate to oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma.

II. Determine the treatment-related toxicity of this drug in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to histologic subtype (indolent vs aggressive).

Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A maximum of 72 patients will be accrued for this study within 2-3 years.

Inclusion criteria

• Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype

• Indolent

• Follicular small cleaved cell
• Follicular mixed cell
• Small lymphocytic
• Mucosa-associated lymphoid tissue (MALT)
• Monocytoid B-cell
• Waldenstrom's macroglobulinemia
• Aggressive

• Follicular large cell
• Diffuse large cell
• Immunoblastic
• Mantle cell
• Ki-1+ NHL
• Peripheral T-cell
• Angiocentric and angioimmunoblastic
• Transformed lymphoma
• Bidimensionally measurable disease
• No more than 3 prior treatment regimens as follows:

• Primary radiotherapy is 1 regimen
• Combined therapy with radiotherapy and chemotherapy is 1 regimen
• Alternating therapy is 1 regimen
• No known brain metastases
• Performance status - ECOG 0-2
• Performance status - Karnofsky 50-100%
• WBC count at least 3,000/mm^3
• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3
• Bilirubin normal
• SGOT/SGPT no greater than 2.5 times upper limit of normal
• Creatinine normal
• Creatinine clearance at least 60 mL/min
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No neuropathy greater than grade 1
• No history of allergy to platinum compounds or antiemetics
• No uncontrolled illness
• No active infection
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No concurrent colony-stimulating factors during first course of therapy
• At least 4 weeks since prior chemotherapy
• At least 4 weeks since prior radiotherapy
• No other concurrent investigational drugs
• No concurrent antiretroviral therapy for HIV-positive patients